Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

No more reading glasses? early trial tests Light-Based corneal treatment

NCT ID NCT07208604

Symptom relief Sponsor: TECLens, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a non-invasive device that uses controlled UV light to reshape the cornea, potentially reducing the need for reading glasses in people with presbyopia. The study will enroll 25 adults aged 40 to 65 with healthy corneas. The main goal is to see if the treatment can safely and accurately correct refractive error within a small range of the target.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Quantitative refractive crosslinking (non-invasive UV light device)
What this could lead to
If successful, this could offer a non-surgical, one-time procedure to reduce or eliminate the need for reading glasses in people with presbyopia.
What could go wrong
This is a very early Phase I trial with only 25 participants, so safety and effectiveness are not yet proven. The procedure may not work for everyone, and there are risks like infection or corneal healing problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 25 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2025

An estimate. Start dates often move.

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 40-65 years * Healthy cornea * Refractive error between +4.0 D and -5.0 D * Phakic or monofocal pseudophakic (≥6 months post IOL placement) * Visual acuity correctable by ±0.25 D Exclusion Criteria: * Corneal dystrophy, scarring, or prior corneal crosslinking * Astigmatism \>1.0 D * Active ocular infection, inflammation, or uncontrolled dry eye * Advanced glaucoma or diabetic retinopathy * History of delayed corneal healing * Pregnancy, breastfeeding, or planning pregnancy during study period * Certain medications (e.g., isotretinoin) * Recent participation in other investigational drug/device studies (within 30 days) * Patients with uncontrolled dry eye or surface disease

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Presbyopia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hyperopia myopia presbyopia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Presbyopia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Asian Eye Institute

    Makati City, Philippines, Philippines

More trials for these conditions

Other studies related to the condition(s) this trial covers.